Amesite Inc.

Listed Company

AMSTCIK 0001807166NasdaqEmerging GrowthServices-Prepackaged SoftwareDelawareFY ends Jun 30

Period

FY 2025

Revenue

$110.5K

Net Income

$-3.62M

Total Assets

$3.10M

Equity

$2.74M

Shares Out

4.57M

Op. Cash Flow

$-2.46M

Business

Amesite Inc. develops and commercializes AI-powered software solutions focused on the healthcare sector, with emphasis on post-acute care. The company offers NurseMagic™, a mobile app and enterprise platform that streamlines nursing documentation, communication, compliance, and workflow efficiency, alongside its Amesite Engage learning platform. Its business is organized into two primary product lines—B2C direct-to-practitioner offerings and a B2B enterprise platform—while maintaining Amesite Engage without growth resources. Amesite distributes via digital channels, self-service onboarding, free trials, targeted marketing, and direct enterprise sales to home health, skilled nursing, hospice, and senior living providers.

Summary from filing dated 2025-09-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net Revenue	110,459	166,881	845,009	697,001	674,580
General and administrative expenses	2	3	2	5	5
Technology and content development	691,154	1	2	3	—
Sales and marketing expenses	545,030	763,915	1	2	2
Total operating expenses	4	5	5	10	9
Loss from Operations	−4	−5	−4	−9	—
Interest income	77,396	176,469	72,824	—	1,593
Impairment expense (Note 3)	−90,869	—	—	—	—
Total other income	−13,473	176,469	71,205	—	—
Net Loss	−4	−4	−4	−9	−12
Basic loss per share (in Dollars per share)	−1.03	−1.73	−1.68	−4.67	−0.59
Diluted loss per share (in Dollars per share)	−1.03	−1.73	−1.68	−4.67	−0.59
Weighted average shares outstanding (in Shares)	4	3	2	2	20

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-11-30
Cash and cash equivalents	2	2	5	—	—
Accounts receivable	6,341	30,060	15,000	—	—
Prepaid expenses and other current assets	94,100	403,489	106,679	560,084	—
Total current assets	2	3	5	8	—
Restricted cash	100,000	100,000	—	—	—
Property and equipment, net of accumulated depreciation of $142,907 and $117,559, respectively	39,436	64,784	88,966	87,190	—
Capitalized software, net of accumulated amortization of $3,757,318 and $3,348,863, respectively	523,804	644,828	778,446	—	—
Total noncurrent assets	663,240	809,612	867,412	1	—
Total assets	3	3	6	9	—
Accounts payable	25,413	48,907	70,070	122,285	—
Accrued compensation	243,198	655,275	64,500	174,056	—
Deferred revenue	36,745	—	53,958	342,672	—
Other accrued liabilities	53,240	94,283	76,799	109,095	—
Total current liabilities	358,596	798,465	265,327	748,108	—
Common stock, $.0001 par value; 100,000,000 shares authorized; 4,572,713 and 2,542,440 shares issued and outstanding at June 30, 2025 and 2024, respectively.	458	255	255	61,250	4,480
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2025 and 2024	—	—	—	0	—
Additional paid-in capital	44	40	40	37	—
Accumulated earnings deficit	−41	−38	−33	−29	—
Total stockholders equity	3	3	6	8	—
Total liabilities and stockholders equity	3	3	6	9	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Depreciation and amortization	433,803	533,667	682,483	875,604	751,498
Stock-based compensation expense	226,053	834,469	179,534	1	876,295
Warrants issued for underwriting fee	95,984	—	—	148,948	1
Forfeiture of accrued director compensation	−200,000	—	—	—	—
Accounts receivable	23,719	−15,060	−455	36,575	10,000
Prepaid expenses and other current assets	309,389	−296,810	453,405	−260,695	−72,115
Accounts payable	−23,494	−21,163	−52,212	77,918	−46,800
Accrued compensation	209,813	590,775	−109,556	—	—
Deferred revenue	36,745	−53,958	−288,714	—	—
Other accrued liabilities	−41,043	17,483	−32,296	—	—
Net cash and cash equivalents used in operating activities	−2	−3	−3	−7	−5
Purchase of property and equipment	—	−1,166	−27,124	−16,575	−73,427
Investment in capitalized software	−378,300	−374,700	—	—	—
Net cash and cash equivalents used in investing activities	−378,300	−375,866	−396,033	−711,622	−842,326
Proceeds from the sale of common stock	3	—	2	4	13
Net cash and cash equivalents provided by financing activity	3	—	2	4	13
Net increase (decrease) in cash, cash equivalents, and restricted cash	262,402	−3	−2	−4	7
Settlement of restricted stock units through common stock issuance to directors	399,975	—	—	—	—
Issuance of common stock for accrued director compensation	21,890	—	—	—	—
Issuance of common stock for public offering consulting expenses	655,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro